Mix with the word of pharma products,people& solutionsJune 19-21,2024.Shanghai New Int’l Expo Centre(SNIEC),Shanghai,China. Manufactory for D-Cloprostenol sodium,DL-Cloprostenol sodium ,Bimatoprost,Bimatoprost amide,Latanoprost,Latanoprostene bunod,Tr..

CHPHI Japan 17 Apr 2024-19 Apr 2024.East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan Manufactory for D-Cloprostenol sodium,DL-Cloprostenol sodium ,Bimatoprost,Bimatoprost amide,Latanoprost,Latanoprostene bunod,Travoprost,Tafluprost,Lubiprostone,Ta..

International Exhibition of Pharmaceuticals, Engineering and Biotechnology April 02 –04, 2024 ExpoForum, St.Petersburg, Russia.Manufactory for D-Cloprostenol sodium,DL-Cloprostenol sodium ,Bimatoprost,Bimatoprost amide,Latanoprost,Latanoprostene b..

Adding daratumumab to lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) in transplant-ineligible patients with newly diagnosed multiple myeloma (MM), regardless of frailty status, according to a subgroup analysis of the MAIA study ..

LAKE ZURICH, Ill.--(BUSINESS WIRE)-- Fresenius Kabi announced today the immediate availability of Temsirolimus Injection in the United States. Fresenius Kabi’s Temsirolimus Injection is supplied as a kit including one vial of 25 mg/mL Temsirolimus solution an..

USA: In a new study, it was found that there was no difference in treatment failure or death between methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) treated with ceftaroline versus MRSA BSI treated with daptomycin. This study wa..

BAR HARBOR — The Food and Drug Administration (FDA) on Jan. 21 expanded the authorized use of Veklury, known commonly as remdesivir, to be used in outpatients 12 years of age and older who test positive for COVID-19.The FDA recommends using the drug for those..

Abstract BACKGROUND Standard therapy for advanced endometrial cancer after failure of platinum-based chemotherapy remains unclear.METHODS In this phase 3 trial, we randomly assigned, in a 1:1 ratio, patients with advanced endometrial cancer who had previous..

The use of denosumab to treat osteoporosis has increased rapidly since its FDA approval in 2010, and it is now the second most used medication after alendronate, according to data presented at the ENDO annual meeting.“Between 2009 and 2020, alendronate was th..